Jun 2026 (Q2 FY26) — Aug 11, 2026
Legend Biotech Q2 FY26 — Strong CARVYKTI Growth and In Vivo CAR-T Progress
Read the full callLegend Biotech (LEGN) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
Legend Biotech earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Price
$18.65 +0.92% · +$0.17
Performance −41.6% 1Y
1Y: $31.96 on 17 Oct 2025 → $18.65. High $36.28 (2 Jun 2026), low $16.65 (4 Feb 2026).
- Previous close
- $18.48
- 52-week range
- $16.65 – $36.28
- One year
- −43.33%
Overview
- Symbol
- LEGN
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 12, 2026
Legend Biotech Q1 FY26 — Strong CARVYKTI Sales and Pipeline Progress
Read the full callDec 2025 (Q4 FY25) — Mar 10, 2026
Legend Biotech Q4 FY25 — CARVYKTI Drives Profitability and Pipeline Expansion
Read the full callEvery analysed call
Legend Biotech earnings calls (LEGN)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total liabilities | — | 124 | 354 | 587 | 597 | 630 | 732 |
| Fixed assets | 28 | 72 | 103 | 105 | 109 | 99 | 116 |
| Total assets | — | 722 | 1,119 | 1,331 | 1,849 | 1,670 | 1,734 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 308 | -83 | -223 | -198 | -201 | -393 | -144 | -100 |
| Cash from investing | -102 | -59 | -24 | -195 | -77 | 93 | -851 | 710 |
| Cash from financing | 3 | 15 | 619 | 627 | 378 | 791 | 6 | -0 |
| Net cash flow | — | — | — | — | — | 492 | -991 | 615 |
| Capital expenditure | -21 | -27 | -26 | -42 | -21 | -20 | -14 | -29 |
| Free cash flow | 287 | -110 | -249 | -241 | -222 | -413 | -158 | -129 |
LEGN operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Global treatment sites | 294Our global growth was driven by continued share gains, site expansion and growing geographic footprint, now reaching 294 global treatment sites across 14 markets worldwide.Source: earnings call transcript | 300+Outside the US demand was supported by continued uptake in established European markets and contributions from recent launches with CARVYKTI now available across 18 global markets and more than 300 global treatment sites.Source: earnings call transcript | 348We recently launched CARVYKTI in Ireland, further expanding availability to 348 global treatment sites, reflecting continued geographic expansion with our partner, J&J Across geographies, we continue to see encouraging trends in both market penetration and earlier line utilization.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
15 filings between Mar 25, 2026 and Sep 29, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$566.8K
5 sales by 4 insiders
Compensation
not trading decisions- 9
- Award — granted as compensation
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Sanders Corazon (Corsee) D. | — | $258.9K | Sep 29, 2026 |
| Huang Ying | — | $169.4K | Jun 25, 2026 |
| Casey Patrick John | — | $88.8K | Jun 30, 2026 |
| Santos Carlos E | — | $49.6K | Sep 21, 2026 |
Latest filings (15)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Sanders Corazon (Corsee) D. Director | Sale | 27,370 | $258.9K |
| Sep 24, 2026 | Sanders Corazon (Corsee) D. Director | Award | 20,986 | $0 |
| Sep 24, 2026 | Mao Li Director | Award | 20,986 | $0 |
| Sep 24, 2026 | Heyman Tomas J. Director | Award | 20,986 | $0 |
| Sep 24, 2026 | Casey Patrick John Director | Award | 20,986 | $0 |
| Sep 24, 2026 | Ji Darren Xiaohui Director | Award | 28,330 | $0 |
| Sep 24, 2026 | Salovey Peter Director | Award | 28,330 | $0 |
| Sep 21, 2026 | Santos Carlos E Chief Financial Officer | Sale | 5,430 | $49.6K |
| Sep 21, 2026 | Santos Carlos E Chief Financial Officer | Award | 19,676 | $0 |
| Sep 15, 2026 | Zhang Ingrid Chief Executive Officer | Award | 1,131,860 | $0 |
| Aug 14, 2026 | BASH ALAN Interim CEO | Award | 4,908 | $0 |
| Jun 30, 2026 | Casey Patrick John Director | Sale | 6,000 | $88.8K |
| Jun 30, 2026 | Huang Ying Chief Executive Officer | Gift | 3,382 | $0 |
| Jun 25, 2026 | Huang Ying Chief Executive Officer | Sale | 5,566 | $82.3K |
| Mar 25, 2026 | Huang Ying Chief Executive Officer | Sale | 9,936 | $87.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Legend Biotech Corp
Free account. Everything above stays public.
Write why you follow Legend Biotech Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading